Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C5H7O3.Ca |
| Molecular Weight | 270.293 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O
InChI
InChIKey=APKDPOQXVKRLEP-UHFFFAOYSA-L
InChI=1S/2C5H8O3.Ca/c2*1-4(6)2-3-5(7)8;/h2*2-3H2,1H3,(H,7,8);/q;;+2/p-2
DescriptionSources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlCurator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.html
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details
Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseHypocalcemia, chronic (treatment) ā Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A novel ubiquitously expressed alpha-latrotoxin receptor is a member of the CIRL family of G-protein-coupled receptors. | 1999 Feb 26 |
|
| [Early stage of cardiomyopathy: mechanisms of damage and compensation]. | 1999 Jul |
|
| D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. | 2000 Dec 15 |
|
| Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. | 2000 Feb 15 |
|
| A family of gamma-like calcium channel subunits. | 2000 Mar 24 |
|
| Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. | 2001 Apr 27 |
|
| Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells. | 2001 Aug |
|
| The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. | 2001 Feb 16 |
|
| Molecular and functional characterization of a family of rat brain T-type calcium channels. | 2001 Feb 9 |
|
| Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. | 2001 Jun |
|
| Vasopressin-stimulated Ca2+ spiking in vascular smooth muscle cells involves phospholipase D. | 2001 Jun |
|
| Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. | 2001 Mar 15 |
|
| Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes. | 2001 Mar 2 |
|
| Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. | 2001 Oct |
|
| Familial intrahepatic cholestasis 1: studies of localization and function. | 2001 Oct |
|
| Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. | 2001 Sep |
|
| Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. | 2002 |
|
| The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
| Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002 Dec |
|
| Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. | 2002 Jul |
|
| Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent. | 2002 Jul 5 |
|
| Human kidney diamine oxidase: heterologous expression, purification, and characterization. | 2002 Jun |
|
| Expression of functional CCR and CXCR chemokine receptors in podocytes. | 2002 Jun 15 |
|
| Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. | 2002 Mar |
|
| Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. | 2002 Mar |
|
| Alpha(1H) mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice. | 2002 Mar 15 |
|
| Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
| Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons. | 2002 Nov 4 |
|
| Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. | 2002 Sep 15 |
|
| A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs. | 2002 Sep 6 |
|
| Effect of calcium phosphate and vitamin Dā supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron. | 2014 Jan 17 |
Sample Use Guides
oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid).
inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA12AA30
Created by
admin on Fri Dec 15 19:14:44 GMT 2023 , Edited by admin on Fri Dec 15 19:14:44 GMT 2023
|
||
|
WHO-ATC |
A12AA30
Created by
admin on Fri Dec 15 19:14:44 GMT 2023 , Edited by admin on Fri Dec 15 19:14:44 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID8060454
Created by
admin on Fri Dec 15 19:14:44 GMT 2023 , Edited by admin on Fri Dec 15 19:14:44 GMT 2023
|
PRIMARY | |||
|
209-725-9
Created by
admin on Fri Dec 15 19:14:44 GMT 2023 , Edited by admin on Fri Dec 15 19:14:44 GMT 2023
|
PRIMARY | |||
|
LLQ966USIL
Created by
admin on Fri Dec 15 19:14:44 GMT 2023 , Edited by admin on Fri Dec 15 19:14:44 GMT 2023
|
PRIMARY | |||
|
SUB13187MIG
Created by
admin on Fri Dec 15 19:14:44 GMT 2023 , Edited by admin on Fri Dec 15 19:14:44 GMT 2023
|
PRIMARY | |||
|
100000076571
Created by
admin on Fri Dec 15 19:14:44 GMT 2023 , Edited by admin on Fri Dec 15 19:14:44 GMT 2023
|
PRIMARY | |||
|
m2951
Created by
admin on Fri Dec 15 19:14:44 GMT 2023 , Edited by admin on Fri Dec 15 19:14:44 GMT 2023
|
PRIMARY | Merck Index | ||
|
591-64-0
Created by
admin on Fri Dec 15 19:14:44 GMT 2023 , Edited by admin on Fri Dec 15 19:14:44 GMT 2023
|
PRIMARY | |||
|
11578
Created by
admin on Fri Dec 15 19:14:44 GMT 2023 , Edited by admin on Fri Dec 15 19:14:44 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
